Fosrenol
Fosrenol (lanthanum carbonate) is a phosphate binder. When taken with meals, it binds to dietary phosphorus in the gastrointestinal tract, preventing its absorption into the body and helping to maintain lower serum phosphorus levels in patients with chronic kidney disease on dialysis.
Dosage by Body Weight
The recommended initial total daily dose for adults is 1,500 mg, divided and taken with or immediately after meals. The dose should be titrated every 2 to 3 weeks in increments of 750 mg per day until an acceptable serum phosphorus level is reached. Chewable tablets must be chewed completely before swallowing to prevent serious gastrointestinal complications.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and effectiveness have not been established in pediatric patients. |
| 5-7 kg | Not recommended | N/A | Safety and effectiveness have not been established in pediatric patients. |
| 8-10 kg | Not recommended | N/A | Safety and effectiveness have not been established in pediatric patients. |
| 11-15 kg | Not recommended | N/A | Safety and effectiveness have not been established in pediatric patients. |
| 16-20 kg | Not recommended | N/A | Safety and effectiveness have not been established in pediatric patients. |
Formulation
Purpose
To reduce serum phosphate levels in patients with end-stage renal disease (ESRD) on dialysis.
Generic Name
Lanthanum carbonateScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.